Role of Biomaterials in treatment of Alzheimer’s disease: A literature review

Abstract

Currently, five medications have been approved by the FDA to treat Alzheimer's disease (AD); Donepezil, which is used at all stages of AD, galantamine, and rivastigmine for mild to moderate stages, and Memantine and a combination of Memantine and donepezil for moderate to severe stages. The ability of these drugs to cross the blood-brain barrier (BBB) determines their exact efficacy. Numerous biomaterials were introduced as a vector for drug agents and increased bioavailability. In this review, we summarized several biomaterials which were used in the treatment of AD.

Keywords

• keywords: alzheimer's disease
• biomaterials
• nanocarriers
• nanoparticles